Gillespie W R, Veng-Pedersen P, Antal E J, Phillips J P
College of Pharmacy, University of Iowa, Iowa City 52242.
J Pharm Sci. 1988 Jan;77(1):48-55. doi: 10.1002/jps.2600770109.
A system approach to the analysis of pharmacodynamic systems is applied to the relationship between the glyburide serum concentration (Cd) and a resulting pharmacologic effect response, that is, the C-peptide serum concentration (Cc) in patients with non-insulin dependent diabetes mellitus (NIDDM). Glyburide, glucose, and C-peptide serum concentrations were measured in eight patients with NIDDM following each of five treatments: Treatment A: one glyburide 5-mg tablet (formulation 1); Treatment B: one glyburide 5-mg tablet (formulation 2); Treatment C: glyburide solution as an intragastric infusion (4.67 mg over 12 h); Treatment D: glyburide solution as an intragastric infusion (9.33 mg over 12 h); and Treatment E: no glyburide. The overall relationship between the C-peptide (Cc), glyburide (Cd), and glucose (Cg) serum concentrations is successfully described by operator equations of the form, Cc(t) = t-infinity psi p(t-u)phi t(Cd(u), Cg(u)) du or Cc(t) = t-infinity psi p(t-u)phi t(Cd(u), Cg(u),u) du. The forms of the individual functions are selected empirically based on the results of the present study and those of previous investigations, and are estimated by conventional curve-fitting procedures. The resulting operator equations are used to describe glyburide pharmacodynamics in NIDDM patients and to estimate the optimal glyburide systemic concentration and delivery rate profiles for such patients based on pharmacodynamic response.
一种用于分析药效学系统的系统方法被应用于非胰岛素依赖型糖尿病(NIDDM)患者中格列本脲血清浓度(Cd)与所产生的药理效应反应(即C肽血清浓度(Cc))之间的关系。在八名NIDDM患者接受以下五种治疗中的每一种后,测量了格列本脲、葡萄糖和C肽的血清浓度:治疗A:一片5毫克格列本脲片剂(制剂1);治疗B:一片5毫克格列本脲片剂(制剂2);治疗C:作为胃内输注的格列本脲溶液(12小时内输注4.67毫克);治疗D:作为胃内输注的格列本脲溶液(12小时内输注9.33毫克);以及治疗E:不使用格列本脲。C肽(Cc)、格列本脲(Cd)和葡萄糖(Cg)血清浓度之间的总体关系通过以下形式的算子方程成功描述:Cc(t) = t到负无穷 psi p(t - u)phi t(Cd(u), Cg(u)) du 或 Cc(t) = t到负无穷 psi p(t - u)phi t(Cd(u), Cg(u), u) du。各个函数的形式是根据本研究结果和先前研究结果凭经验选择的,并通过传统的曲线拟合程序进行估计。所得的算子方程用于描述NIDDM患者中的格列本脲药效学,并根据药效学反应估计此类患者的最佳格列本脲全身浓度和给药速率曲线。